The Food and Drug Administration today adjusted its import screening to expedite personal protective equipment and clarified types of PPE that can be imported without engaging with FDA. To provide flexibility, FDA will facilitate access to critical legitimate PPE and devices and monitor the import systems to prevent and mitigate potential issues.

FDA established an email, COVID19FDAIMPORTINQUIRIES@fda.hhs.gov, for industry representatives to address questions or concerns. FDA also updated its FAQ on diagnostic testing for SARS-CoV-2 to answer additional questions

Related News Articles

Headline
In a study of more than 4,900 health care workers across 33 sites in 25 U.S. states, the Pfizer and Moderna COVID-19 vaccines were 89% and 96% effective,…
Headline
The AHA today released the latest edition of the COVID-19 Snapshot, underscoring the persisting challenges facing hospitals and health systems during the…
Headline
The Food and Drug Administration today required certain COVID-19 test developers to evaluate how SARS-CoV-2 mutations impact their test’s performance and…
Headline
The Food and Drug Administration late last night amended Pfizer’s emergency use authorization for its COVID-19 vaccine to allow for an additional, booster…
Headline
In AHA’s newest #MyWhy video, nine hospital employees from UAB Medicine in Alabama candidly discuss their COVID-19 vaccine experience, starting with initial…
Headline
The Centers for Medicare & Medicaid Services yesterday began publicly sharing COVID-19 vaccination rates for nursing home staff and residents on its Care…